Table of Contents
Chromatography Research International
Volume 2011, Article ID 243491, 7 pages
http://dx.doi.org/10.4061/2011/243491
Research Article

Development and Validation of New Chromatographic Method for the Determination of Enantiomeric and Diastereomeric Purity of Solifenacin Succinate: An Antimuscarinic Agent

1Research and Development, Megafine Pharma (P) Ltd., Nashik 422202, India
2Department of Chemistry, Organic Chemistry Research Center, K.R.T. Arts, B.H. Commerce and A.M. Science College, Gangapur Road, Nashik 422002, India
3Daicel Chiral Technologies (India) Pvt. Ltd., Hyderabad 500078 AP, India

Received 27 July 2010; Accepted 27 September 2010

Academic Editor: Cristina Minguillón

Copyright © 2011 Shashikant B. Landge et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Cardozo, M. Lisec, and M. Lisec, “Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder,” Journal of Urology, vol. 172, no. 5, pp. 1919–1924, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Smulders, W. J. Krauwinkel, P. J. Swart, and M. Huang, “Pharmacokinetics and safety of solifenacin succinate in healthy young men,” Journal of Clinical Pharmacology, vol. 44, no. 9, pp. 1023–1033, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. T. Yanagihara, T. Aoki, Y. Soeishi, T. Iwatsubo, and H. Kamimura, “Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography,” Journal of Chromatography B, vol. 859, no. 2, pp. 241–245, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. Wagg, J.-J. Wyndaele, and P. Sieber, “Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis,” American Journal Geriatric Pharmacotherapy, vol. 4, no. 1, pp. 14–24, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. K. Ikeda, S. Kobayashi, M. Suzuki, K. Miyata, M. Takeuchi, T. Yamada, and K. Honda, “M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 366, no. 2, pp. 97–103, 2002. View at Publisher · View at Google Scholar · View at PubMed
  6. M. C. Michel, M. Oelke, and N. Zinner, “Novel muscarinic antagonists to treat incontinence and/or overactive bladder,” Drug Discovery Today: Therapeutic Strategies, vol. 2, no. 1, pp. 1–6, 2005. View at Publisher · View at Google Scholar
  7. http://www.medilexicon.com/drugs/vesicare.php.
  8. R. Naito, Y. Yonetoku, Y. Okamoto, A. Toyoshima, K. Ikeda, and M. Takeuchi, “Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists,” Journal of Medicinal Chemistry, vol. 48, no. 21, pp. 6597–6606, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. N. C. Niphade, K. M. Jagtap, A. C. Mali, P. V. Solanki, M. N. Jachak, and V. T. Mathad, “Efficient and single pot process for the preparation of enantiomerically pure solifenacin succinate: an antimuscarinic agent,” Monatshefte Fur Chemie. In press.
  10. http://www.chiraltech.com/app/IC_0607.pdf.
  11. P. Franco and T. Zhang, “Common approaches for efficient method development with immobilised polysaccharide-derived chiral stationary phases,” Journal of Chromatography B, vol. 875, no. 1, pp. 48–56, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. T. Zhang, D. Nguyen, and P. Franco, “Enantiomer resolution screening strategy using multiple immobilised polysaccharide-based chiral stationary phases,” Journal of Chromatography A, vol. 1191, no. 1-2, pp. 214–222, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. T. Zhang, D. Nguyen, P. Franco, Y. Isobe, T. Michishita, and T. Murakami, “Cellulose tris(3,5-dichlorophenylcarbamate) immobilised on silica: a novel chiral stationary phase for resolution of enantiomers,” Journal of Pharmaceutical and Biomedical Analysis, vol. 46, no. 5, pp. 882–891, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. H. Y. Aboul-Enein, “High-performance liquid chromatographic enantioseparation of drugs containing multiple chiral centers on polysaccharide-type chiral stationary phases,” Journal of Chromatography A, vol. 906, no. 1-2, pp. 185–193, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Masatoshi, “Process for prodcuing solifenacin or its salt,” EP. Pat., 1757604 A1, 2007.
  16. P. Jordi, S. Laura, M. Ester, A. Ignasi, and B. Jordi, “An improved process for the synthesis of solifenacin,” WO 2008/062282 A2, 2008.
  17. The United States Pharmacopeia, Validation of Compendial Methods, USP, Rockville, Md, USA, 32nd edition, 2009.
  18. International Federation of Pharmaceutical Manufactures & Associations (IFPMA), “Validation of analytical procedure,” in Proceedings of International Conference on Harmonization (ICH '96), Geneva, Switzerland, 1996, Methodology Q2(R1).